Q4 FY2025 Earnings
Financial report interval: 2025.10.01 - 2025.12.31
Overview: MABPHARM-B(02181) the Revenue is 206.79 M (+159.6%);the EBIT is 1.08 M (+107.6%);the EPS is 0.0052 (+197.2%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.21B159.61%
----
----
EBIT
0.00B107.59%
----
----
EPS
0.0052197.17%
----
----
Revenue
ActualEstimateUnit: HKD
qf
EBIT
ActualEstimateUnit: HKD
qf
Net income
ActualEstimateUnit: HKD
qf
EPS
ActualEstimateUnit: HKD
qf